How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

28,354 results for

Topical Corticosteroid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x (...) × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated

2018 Clinical Trials

62. A clinicoepidemiological study of topical corticosteroid misuse at a tertiary care centre. (Abstract)

A clinicoepidemiological study of topical corticosteroid misuse at a tertiary care centre. Misuse of topical corticosteroids (TCS) has become a burning issue in many countries across the globe. Non-prescriptional sale, lack of awareness and non availability of qualified dermatologist are some of the contributing factors.To assess the clinicoepidemiological profile of patients misusing TCS and assess various factors contributing to it.All the patients presenting to the dermatology OPD (...) of a tertiary care centre were screened by asking for application of any topical medication. Those patients who were found to be using TCS inappropriately as per clinical diagnosis were included in the study.A total of 324 out of 8621 (3.76%) patients were included in the study. Maximum number of patients belonged to the age - group of 21-30 years. The most common steroid was clobetasol followed by mometasone and beclomethasone. The most common primary dermatosis was dermatophytosis followed by acne

2018 Journal of Dermatological Treatment

63. A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record (...) Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (AD Up) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal

2018 Clinical Trials

64. A Randomized Trial of Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis

A Randomized Trial of Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis A Randomized Trial of Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved (...) Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Randomized Trial of Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical

2018 Clinical Trials

65. Potency of Topical Corticosteroids in Combination Preparations

Potency of Topical Corticosteroids in Combination Preparations Potency of Topical Corticosteroids in Combination Preparations - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Potency of Topical (...) University of the Negev Collaborator: Soroka University Medical Center Information provided by (Responsible Party): Alex Zvulunov, Ben-Gurion University of the Negev Study Details Study Description Go to Brief Summary: Several combination topical drugs are available on the market. The potency of corticosteroids depends on a particular molecular structure and the skin penetration properties. Besides molecular structure, a penetration of a corticosteroid molecule correlates with physical properties

2018 Clinical Trials

66. Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone

Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your

2018 Clinical Trials

67. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation – JOELLE study) Full Text available with Trip Pro

A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation – JOELLE study) There is a concern that topical tacrolimus and pimecrolimus, indicated for second-line treatment of atopic dermatitis, may increase the risk of lymphoma and skin cancer, particularly in children.The aim of this study was to compare incidence rates (IRs) of lymphoma and skin cancer between new (...) users of topical tacrolimus or pimecrolimus and users of moderate- to high-potency topical corticosteroids (TCSs) and untreated subjects.This is a multicenter cohort study with frequency matching by strata of propensity scores in population databases in the Netherlands, Denmark, Sweden, and the UK. IR ratios (IRRs) were estimated using Mantel-Haenszel methods for stratified analysis.We included 19,948 children and 66,127 adults initiating tacrolimus, 23,840 children and 37,417 adults initiating

2018 Clinical epidemiology

68. A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable

A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically (...) Advisable - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled

2018 Clinical Trials

69. Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's Disease

Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's Disease Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's Disease (BD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03771768 Recruitment Status : Not yet recruiting

2018 Clinical Trials

70. Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis Who Are Not Adequately Controlled With or Have Contraindications to Oral Cyclosporine A

Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis Who Are Not Adequately Controlled With or Have Contraindications to Oral Cyclosporine A Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis Who Are Not Adequately Controlled With or Have Contraindications to Oral Cyclosporine A - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration (...) or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis Who Are Not Adequately Controlled With or Have Contraindications to Oral Cyclosporine A (ECZTRA 7) The safety and scientific validity of this study is the responsibility of the study sponsor

2018 Clinical Trials

71. Efficacy and Safety of Topical corticosteroid Eye Drops in the Treatment of Dry Eye Syndrome: a Systematic Review and Meta-analysis

Efficacy and Safety of Topical corticosteroid Eye Drops in the Treatment of Dry Eye Syndrome: a Systematic Review and Meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2020 PROSPERO

72. High-dose inhaled corticosteroids in asthma

High-dose inhaled corticosteroids in asthma Asthma: medicines safety priorities Asthma: medicines safety priorities Key therapeutic topic Published: 15 January 2015 nice.org.uk/guidance/ktt5 pathways K Ke ey points y points Inhaled corticosteroids (ICS) are the first-choice regular preventer therapy for adults, young people and children with asthma. When long-acting beta agonists (LABAs) are prescribed for people with asthma, they should be prescribed with an ICS. LABAs should not be used (...) , including self-monitoring and a follow- up with a healthcare professional. Review and update the person's asthma action plan when decreasing maintenance therapy. Prolonged use of high doses of ICS (as with the use of oral corticosteroids) carries a risk of systemic side effects, including adrenal suppression, growth retardation in children and young people, decreased bone mineral density, cataracts, glaucoma, and psychological or behavioural effects. (See the following links for more details: MHRA 2006

2015 National Institute for Health and Clinical Excellence - Advice

73. Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

Use in Adults With Oral Corticosteroid Dependent Asthma (SOURCE) Actual Study Start Date : March 5, 2018 Estimated Primary Completion Date : November 26, 2020 Estimated Study Completion Date : November 26, 2020 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Tezepelumab Tezepelumab subcutaneous injection Biological: Tezepelumab Tezepelumab subcutaneous injection Placebo Comparator: Placebo Placebo (...) Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2018 Clinical Trials

74. Corticosteroid(CS) + Lido or Corticosteroid(CS) Alone

: Treatment Official Title: Corticosteroid(CS) Injections for the Treatment of Common Upper Extremity Pathologies, With or Without Lidocaine Estimated Study Start Date : March 2019 Estimated Primary Completion Date : August 2021 Estimated Study Completion Date : August 2021 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Treatment Group (corticosteroid injection plus lidocaine) Treatment (...) Corticosteroid(CS) + Lido or Corticosteroid(CS) Alone Corticosteroid(CS) + Lido or Corticosteroid(CS) Alone - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Corticosteroid(CS) + Lido or Corticosteroid(CS

2018 Clinical Trials

75. A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease

Photopheresis (ECP) as First-line Treatment of Standard Risk Grade II Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation Estimated Study Start Date : October 1, 2018 Estimated Primary Completion Date : April 1, 2021 Estimated Study Completion Date : April 1, 2022 Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Experimental group corticosteroids + ECP Combination (...) A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search

2018 Clinical Trials

76. Antenatal Corticosteroid Therapy for Fetal Maturation

from repeated courses (especially in the reduction and severity of respiratory distress), there also are animal and human data that suggest deleterious effects on the fetus regarding cerebral myelination, lung growth, and function of the hypothalamic–pituitary–adrenal axis. Follow-up of children at 2 years of age who were exposed to repeat courses of antenatal corticosteroids showed no significant difference in physical or neurocognitive measures in two studies ( , ), and the same outcome was found (...) in younger children in a third study ( ). Although not statistically significant, the relative risk of cerebral palsy in infants exposed to serial courses of antenatal corticosteroids (RR, 5.7; 95% confidence interval, 0.7–46.7; P =.12) in one study is of concern and warrants further study (39). Maternal effects include increased risk of infection and suppression of the hypothalamic–pituitary–adrenal axis ( , ). Regularly scheduled repeat courses or serial courses (more than two) are not currently

2017 American College of Obstetricians and Gynecologists

77. Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I)

): Moderator at Annual Meeting, the European Society of Intensive Care Medicine (EISCM) (co-chair of Corticosteroid Guideline in collaboration with SCCM), and the Korean Society of Critical Care Medicine (co-director and speaker at Multiprofessional Critical Care Board Review Course). He has spoken on the topic of corticosteroid use in critical illness and specifically in sepsis at the International Symposium in Critical and Emergency Medicine in March 2017. Dr. Arlt participates in the Society (...) ACTH (1 μg) stimulation test with total random cortisol for diagnosis of adrenal insufficiency in 59 adults with septic shock ( ). Compared with total random cortisol, the low-dose ACTH test was better able to predict a longer duration of vasopressor requirement and hemodynamic response to corticosteroids . Similarly, prospective cohort studies in adults with or without sepsis ( ) and in patients with multiple trauma ( ) found that patients with CIRCI, i.e., total cortisol levels < 10 μg/dL

2017 Society of Critical Care Medicine

78. Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects

Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects - GOV.UK GOV.UK uses cookies to make the site simpler. Search Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects Coadministration of a corticosteroid with an HIV-treatment-boosting agent may increase the risk of adrenal (...) the action of some antiretroviral medicines. Corticosteroids are mainly metabolised by the CYP3A enzyme group, particularly CYP3A4. Therefore, use of a CYP3A inhibitor with a corticosteroid is anticipated to increase systemic steroid levels. Cobicistat An EU-wide review has identified 8 cases worldwide (including 1 published report ) of adrenal suppression during treatment with a cobicistat-containing regimen (Stribild) and subsequent prescription of an inhaled, intranasal, or intra-articular

2017 MHRA Drug Safety Update

79. Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information (...) . Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does

2017 Clinical Trials

80. Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase Full Text available with Trip Pro

Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase Atopic dermatitis is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) is a widely used, potent immunosuppressant but it is not effective in all patients with atopic dermatitis, and side-effects limit (...) its use. Dupilumab, a fully human anti-interleukin 4 receptor-alpha monoclonal antibody, inhibits signaling of IL-4 and IL-13, key drivers of Type 2/Th2-mediated inflammation, and is approved in the U.S.A. and the European Union for the treatment of inadequately-controlled moderate-to-severe atopic dermatitis in adults.To evaluate efficacy and safety of dupilumab with concomitant topical corticosteroids (TCS) in adults with atopic dermatitis with inadequate response to/intolerance of CsA

2017 British Journal of Dermatology Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>